RESUMEN
Innate immunity not only shapes the way epithelial barriers interpret environmental cues but also drives adaptive responses. Therefore, modulators of innate immune responses are expected to have high therapeutic potential across immune-mediated inflammatory diseases. IRAK4 is a kinase that integrates signaling downstream of receptors acting at the interface between innate and adaptive immune responses, such as Toll-like receptors (TLRs), interleukin-1R (IL-1R), and IL-18R. Because effects of IRAK4 inhibition are stimulus, cell type, and species dependent, the evaluation of the therapeutic potential of IRAK4 inhibitors requires a highly translational approach. Here, we profiled a selective IRAK4 inhibitor, GLPG2534, in an extensive panel of models of inflammatory skin diseases, translationally expanding evidence from in vitro to in vivo and from mouse to human. In vitro, IRAK4 inhibition resulted in substantial inhibition of TLR and IL-1 responses in dendritic cells, keratinocytes, granulocytes, and T cells but only weakly affected dermal fibroblast responses. Furthermore, disease activity in murine models of skin inflammation (IL-23-, IL-33-, imiquimod-, and MC903-induced) was markedly dampened by IRAK4 inhibition. Last, inhibiting IRAK4 reversed pathogenic molecular signatures in human lesional psoriasis and atopic dermatitis biopsies. Over the variety of models used, IRAK4 inhibition consistently affected central mediators of psoriasis (IL-17A) and atopic dermatitis (IL-4 and IL-13). Overall, our data highlight IRAK4 as a central player in skin inflammatory processes and demonstrate the potential of IRAK4 inhibition as a therapeutic strategy in chronic inflammatory skin diseases.
Asunto(s)
Dermatitis Atópica , Psoriasis , Humanos , Ratones , Animales , Quinasas Asociadas a Receptores de Interleucina-1/metabolismo , Dermatitis Atópica/patología , Transducción de Señal , Receptores Toll-Like/uso terapéutico , Piel/patología , Psoriasis/tratamiento farmacológicoRESUMEN
BACKGROUND: cerebral malaria (CM) is an important complication of malaria with a high mortality rate. Artesunate is recommended as the first-line artemisinin compound treatment for severe malaria. Due to the difficulty of obtaining brain tissue samples clinically, the use of animals to research host responses to CM parasite infections is necessary. Rodent malaria models allow for detailed time series studies of host responses in multiple organs. To date, studies on the transcriptome of severe malaria are only limited to the parasites in the peripheral blood of patients, and there is little data on the transcriptional changes in brain tissue in mice with CM treated with artesunate. METHOD AND RESULT: in this study, fresh tissue samples (three biological replicates per mouse) from the same area of the brain in each animal were collected from the uninfected, Plasmodium berghei ANKA-infected and artesunate-treated C57BL/6 mice, and then transcriptome research was performed by the RNA-seq technique. Differentially expressed genes (DEGs) included Il-21, Tnf, Il-6, Il-1ß, Il-10, Ifng, and Icam-1. Among which, Il-6, Il-10, Tnf-α and Il-1ß were further verified and validated via qRT-PCR and ELISA. This revealed that Il-1ß (p < 0.0001), Il-10 (p < 0.05) and Tnf-α (p < 0.05) were significantly up-regulated in the Pb ANKA-infected versus uninfected group, while Il-1ß (p < 0.0001) and Tnf-α (p < 0.05) were significantly down-regulated after artesunate treatment. All DEGs were closely related to the top 3 artesunate treatment pathways, including the JAK-STAT signaling pathway, apoptosis, and Toll-like receptor signaling pathway. CONCLUSION: the mechanism of improving the prognosis of cerebral malaria by artesunate may not only involve the killing of plasmodium but also the inhibition of a cytokine storm in the host. This study provides new insights into the molecular mechanism by which artesunate improves the prognosis of cerebral malaria.
Asunto(s)
Antimaláricos , Artemisininas , Malaria Cerebral , Animales , Antiinflamatorios/uso terapéutico , Antimaláricos/farmacología , Antimaláricos/uso terapéutico , Artemisininas/farmacología , Artemisininas/uso terapéutico , Artesunato/farmacología , Artesunato/uso terapéutico , Modelos Animales de Enfermedad , Perfilación de la Expresión Génica , Molécula 1 de Adhesión Intercelular/uso terapéutico , Interleucina-10/uso terapéutico , Interleucina-6/uso terapéutico , Plomo/uso terapéutico , Malaria Cerebral/tratamiento farmacológico , Malaria Cerebral/genética , Malaria Cerebral/metabolismo , Ratones , Ratones Endogámicos C57BL , RNA-Seq , Receptores Toll-Like/uso terapéutico , Factor de Necrosis Tumoral alfa/uso terapéuticoRESUMEN
Ischemic reperfusion injury (IRI) of the kidneys is a direct sequela of surgical procedures associated with the interruption of blood supply. The pathophysiology of IRI is complicated, and several inflammatories, apoptosis, and oxidative stress pathways are implicated. Among the major receptors directly involved in renal IRI are the toll-like receptors (TLRs), specifically TLR2 and TLR4. In this study, we investigated the effects of Lipopolysaccharide from Rhodobacter Sphaeroides (TLR2 and TLR4 antagonist, LPS-RS) and the ultrapure form (pure TLR4 antagonist, ULPS-RS) on the histopathological changes and TLRs expression in an animal model of bilateral renal IRI. Forty-eight adult male rats were allocated into six groups (N=8) as follows: sham group (negative control without IRI), control group (rats underwent bilateral renal ischemia for 30 minutes and 2 hours of reperfusion), vehicle group (IRI+ vehicle), LPS-RS group (IRI+ 0.5 mg/kg of LPS-RS), ULPS-RS group (IRI+ 0.1 mg/kg of ULPS-RS), ULPS-RSH group (IRI+ 0.2 mg/kg of ULPS-RS). Significant improvement in the histopathological damages induced by renal IRI was found in the ULPS-RS treated groups at both doses compared with the control group. The protective effect of ULPS-RS was associated with significantly reduced TLR4 expression without affecting TLR2. Regarding LPS-RS, the tested dose adversely affected the renal tissues as manifested by the histopathological findings, although it similarly affected TLRs expression as ULPS-RS. Our results demonstrated that ULPS-RS was renoprotective while LPS-RS had no protective effect against the tissue damages induced by renal IRI.
Asunto(s)
Lipopolisacáridos , Daño por Reperfusión , Animales , Riñón/irrigación sanguínea , Lipopolisacáridos/farmacología , Lipopolisacáridos/uso terapéutico , Masculino , Modelos Animales , Ratas , Daño por Reperfusión/complicaciones , Daño por Reperfusión/tratamiento farmacológico , Daño por Reperfusión/metabolismo , Rhodobacter/metabolismo , Receptor Toll-Like 2/metabolismo , Receptor Toll-Like 4/metabolismo , Receptor Toll-Like 4/uso terapéutico , Receptores Toll-Like/uso terapéuticoRESUMEN
One of the most common diabetic microvascular complications is diabetic neuropathy (DN). Immune cell infiltration in the peripheral nerve system (PNS), myelin loss, Schwann cell death, and axonal damage are all hallmarks of DN, which is currently believed to be a chronic inflammatory disease. Toll-like receptors (TLRs) are found in various types of nervous system cells, including Schwann cells, microglia, oligodendrocytes, astrocytes, and neurons. Proinflammatory mediators released at the end of TLR signal transduction can trigger an inflammatory response involving the nervous system. Studies on the association between TLRs and DN began as early as 2004. Since then, several studies have been conducted to assess the involvement of TLRs in the pathogenesis of DN. The focus of this review is to give a complete summary of the researches that have been done in this context, as well as an overview of the role of TLRs and their therapeutic applications in DN.
Asunto(s)
Neuropatías Diabéticas/tratamiento farmacológico , Receptores Toll-Like/uso terapéutico , Animales , Humanos , Receptores Toll-Like/fisiologíaRESUMEN
Toll-like receptors (TLRs) receptors are responsible for initiation of inflammatory responses by their recognition of molecular patterns present in invading microorganisms (such as bacteria, viruses or fungi) or in molecules released following tissue damage in disease states. Expressed in the intestinal epithelium, they initiate an intracellular signalling cascade in response to molecular patterns resulting in the activation of transcription factors and the release of cytokines, chemokines and vasoactive molecules. Intestinal epithelial cells are exposed to microorganisms on a daily basis and form part of the primary defence against pathogens by using TLRs. TLRs and their accessory molecules are subject to tight regulation in these cells so as to not overreact or react in unnecessary circumstances. TLRs have more recently been associated with chronic inflammatory diseases as a result of inappropriate regulation, this can be damaging and lead to chronic inflammatory diseases such as inflammatory bowel disease (IBD). Targeting Toll-like receptors offers a potential therapeutic approach for IBD. In this review, the current knowledge on the TLRs is reviewed along with their association with intestinal diseases. Finally, compounds that target TLRs in animal models of IBD, clinic trials and their future merit as targets are discussed.
Asunto(s)
Enfermedades Inflamatorias del Intestino , Receptores Toll-Like , Animales , Citocinas , Humanos , Inmunidad Innata , Enfermedades Inflamatorias del Intestino/tratamiento farmacológico , Mucosa Intestinal , Transducción de Señal/fisiología , Receptores Toll-Like/fisiología , Receptores Toll-Like/uso terapéuticoRESUMEN
BACKGROUND: Hepatitis C virus (HCV) infection is a worldwide issue. However, the current treatment for hepatitis C has many shortcomings. Toll-like receptors (TLRs) are pattern recognition receptors involved in HCV infection, and an increasing number of studies are focusing on the role of TLRs in the progression of hepatitis C. DATA SOURCES: We performed a PubMed search up to January 2021 with the following keywords: hepatitis C, toll-like receptors, interferons, inflammation, and immune evasion. We also used terms such as single-nucleotide polymorphisms (SNPs), susceptibility, fibrosis, cirrhosis, direct-acting antiviral agents, agonists, and antagonists to supplement the query results. We reviewed relevant publications analyzing the correlation between hepatitis C and TLRs and the role of TLRs in HCV infection. RESULTS: TLRs 1-4 and 6-9 are involved in the process of HCV infection. When the host is exposed to the HCV, TLRs, as important participants in HCV immune evasion, trigger innate immunity to remove the virus and also promote inflammation and liver fibrosis. TLR gene SNPs affect hepatitis C susceptibility, treatment, and prognosis. The contribution of each TLR to HCV is different. Drugs targeting various TLRs are developed and validated, and TLRs can synergize with classic hepatitis C drugs, including interferon and direct-acting antiviral agents, constituting a new direction for the treatment of hepatitis C. CONCLUSIONS: TLRs are important receptors in HCV infection. Different TLRs induce different mechanisms of virus clearance and inflammatory response. Although TLR-related antiviral therapy strategies exist, more studies are needed to explore the clinical application of TLR-related drugs.
Asunto(s)
Hepatitis C Crónica , Hepatitis C , Antivirales/uso terapéutico , Hepacivirus/genética , Hepatitis C/tratamiento farmacológico , Hepatitis C/genética , Hepatitis C Crónica/tratamiento farmacológico , Hepatitis C Crónica/genética , Humanos , Receptores Toll-Like/agonistas , Receptores Toll-Like/uso terapéuticoRESUMEN
BACKGROUND: We performed a clinical trial to evaluate safety and immunogenicity of a novel long peptide vaccine administered in combinations of incomplete Freund's adjuvant (IFA) and agonists for TLR3 (polyICLC) and TLR7/8 (resiquimod). We hypothesized that T cell responses to minimal epitope peptides (MEPs) within the long peptides would be enhanced compared with prior vaccines with MEP themselves and that T cell responses would be enhanced with TLR agonists, compared with IFA alone. METHODS: Participants with resected stage IIB-IV melanoma were vaccinated with seven long melanoma peptides (LPV7) from tyrosinase, gp100, MAGE-A1, MAGE-A10, and NY-ESO-1, each containing a known MEP for CD8+ T cells, plus a tetanus helper peptide (Tet) restricted by Class II MHC. Enrollment was guided by an adaptive design to one of seven adjuvant combinations. Vaccines were administered at weeks 1, 2, 3, 6, 9, 12 at rotating injection sites. T cell and IgG antibody (Ab) responses were measured with IFN-gamma ELIspot assay ex vivo and ELISA, respectively. RESULTS: Fifty eligible participants were assigned to seven study groups, with highest enrollment on arm E (LPV7+Tet+IFA+polyICLC). There was one dose-limiting toxicity (DLT) in Group E (grade 3 injection site reaction, 6% DLT rate). All other treatment-related adverse events were grades 1-2. The CD8+ T cell immune response rate (IRR) to MEPs was 18%, less than in prior studies using MEP vaccines in IFA. The CD8+ T cell IRR trended higher for IFA-containing adjuvants (24%) than adjuvants containing only TLR agonists (6%). Overall T cell IRR to full-length LPV7 was 30%; CD4+ T cell IRR to Tet was 40%, and serum Ab IRR to LPV7 was 84%. These IRRs also trended higher for IFA-containing adjuvants (36% vs 18%, 48% vs 24%, and 97% vs 60%, respectively). CONCLUSIONS: The LPV7 vaccine is safe with each of seven adjuvant strategies and induced T cell responses to CD8 MEPs ex vivo in a subset of patients but did not enhance IRRs compared with prior vaccines using short peptides. Immunogenicity was supported more by IFA than by TLR agonists alone and may be enhanced by polyICLC plus IFA. TRIAL REGISTRATION NUMBER: NCT02126579.
Asunto(s)
Melanoma/tratamiento farmacológico , Receptores Toll-Like/uso terapéutico , Vacunas de Subunidad/uso terapéutico , Femenino , Humanos , Masculino , Factores de Riesgo , Vacunas de Subunidad/farmacologíaRESUMEN
Toll-like receptors (TLRs) are pattern recognition receptors which mediate an inflammatory response upon the detection of specific molecular patterns found on foreign organisms and on endogenous damage-related molecules. These receptors play a major role in the activation of microglia, the innate immune cells of the CNS, and are also expressed in peripheral tissues, including blood mononuclear cells and the gut. It is well established that immune activation, in both the brain and periphery, is a feature of Parkinson's disease as well as other α-synucleinopathies. Aggregated forms of α-synuclein can act as ligands for TLRs (particularly TLR2 and TLR4), and hence these receptors may play a critical role in mediating a detrimental immune response to this protein, as well as other inflammatory signals in Parkinson's and related α-synucleinopathies. In this review, the potential role of TLRs in contributing to the progression of these disorders is discussed. Existing evidence comes predominantly from studies in in vitro and in vivo models, as well as analyses of postmortem human brain tissue and pre-clinical studies of TLR inhibitors. This evidence is evaluated in detail, and the potential for therapeutic intervention in α-synucleinopathies through TLR inhibition is discussed.
Asunto(s)
Enfermedad de Parkinson/metabolismo , Enfermedad de Parkinson/terapia , Sinucleinopatías/metabolismo , Receptores Toll-Like/uso terapéutico , Animales , Encéfalo/metabolismo , Humanos , Microglía/metabolismo , Trastornos Parkinsonianos/metabolismo , Trastornos Parkinsonianos/terapia , Sinucleinopatías/terapia , Receptor Toll-Like 2/metabolismo , Receptor Toll-Like 4/metabolismo , Receptores Toll-Like/metabolismo , alfa-Sinucleína/metabolismoRESUMEN
The pathogenesis of systemic autoimmune diseases such as systemic lupus erythematosus (SLE) is based on the loss of self-tolerance against ubiquitous autoantigens involving all mechanisms of adaptive immunity. However, data accumulating over the last decade imply an important role also for numerous elements of innate immunity, namely the Toll-like receptors in the pathogenesis of SLE. Here we discuss their role in the most common organ complication of SLE, i.e. lupus nephritis. We summarize experimental and clinical data on the expression and functional contribution of the Toll-like receptors in immune complex glomerulonephritis, and intrarenal inflammation. Based on these discoveries Toll-like receptors are evolving as therapeutic targets for the treatment of SLE and lupus nephritis.
Asunto(s)
Nefritis Lúpica/terapia , Receptores Toll-Like/uso terapéutico , Humanos , Inflamación/genética , Inflamación/inmunología , Inflamación/terapia , Nefritis Lúpica/genética , Nefritis Lúpica/inmunologíaRESUMEN
O Herpes simples tipo 1 (HSV-1) é um vírus neurotrópico que causa sintomas brandos mas também, em alguns casos, cegueira e encefalite. Estudos anteriores demonstraram que a resposta imune contra o HSV-1 ocorre principalmente no gânglio trigêmeo (GT) e que os receptores do tipo Toll 2 e 9 (TLR2/9) são importantes na mediação desta resposta. Adicionalmente, foi evidenciado que a enzima iNOS (óxido nítrico sintase) e a interleucina 1 beta (IL-1β) têm papel essencial na defesa contra a infecção por HSV-1. Assim, o presente trabalho teve como objetivo identificar as principais células responsáveis pela produção de iNOS e IL-1β, bem como, avaliar outras importantes células e moléculas que podem ou não dependerem dos receptores TLR2/9 para mediar a resposta imune contra o HSV-1. Para tanto, camundongos C57BL/6 (selvagens, WT) e TLR2/9-/- foram infectados por via intranasal com 1 x 106 p.f.u. de HSV-1. Para análise das populações de células, suspensões celulares do GT e baço de animais WT e TLR2/9-/-, infectados e não infectados, foram obtidas e analisadas por citometria de fluxo. A porcentagem de células produtoras de iNOS, IL-1β, granzima B e perforina também foi determinada por citometria de fluxo. Os mRNAs das quimiocinas MCP-1 (proteína quimiotática de monócitos 1) e IP-10 (proteína 10 induzida por interferon gama (IFN-γ)) foram quantificados no pulmão e na traqueia por PCR em tempo real. A quimiocina MCP-1 também foi quantificada em nível de proteína, contudo, por Cytometric Bead Array (CBA) no GT, baço, linfonodo e pulmão.
As expressões dos transcritos de IL-1β, dos IFNs do tipo I, das interleucinas 5 e 10 (IL-5 e IL-10) e da granzima B foram quantificados por real time PCR. Os resultados indicam que as células dendríticas (DCs) e os monócitos/macrófagos (Mo/Mɸ) são as principais células produtoras de IL-β e iNOS, respectivamente, e que, junto com os IFNs do tipo I, são essenciais para a resposta imune contra o HSV-1. Além disso, demonstramos que a granzima B produzida por linfócitos T CD8+ e células NK e, as quimiocinas MCP-1 e IP-10 são também importantes para esta resposta imune. Do mesmo modo, nossos dados indicam que os níveis substanciais de MCP-1, IP-10 e granzima B ou são TLR-independentes ou regulados por estes receptores no GT de camundongos TLR2/9-/- infectados. Assim, nossos dados fornecem forte evidência de que as respostas mediadas por DCs, Mo/Mɸ, NK e linfócitos T CD8+ através da produção de IL-1β, iNOS e granzima B, respectivamente, em conjunto com a precoce produção dos IFNs do tipo I no início da infecção, são cruciais para a defesa do hospedeiro contra o HSV-1.
Asunto(s)
Masculino , Femenino , Humanos , Herpes Simple/prevención & control , Inmunidad Innata/inmunología , Receptores Toll-Like/uso terapéuticoRESUMEN
TLRs recognize microbial pathogens and trigger an immune response, but their regulation by neuropeptides, such as vasoactive intestinal peptide (VIP), during Pseudomonas aeruginosa corneal infection remains unexplored. Therefore, C57BL/6 (B6) mice were injected i.p. with VIP, and mRNA, protein, and immunostaining assays were performed. After VIP treatment, PCR array and real-time RT-PCR demonstrated that proinflammatory TLRs (conserved helix-loop-helix ubiquitous kinase, IRAK1, TLR1, TLR4, TLR6, TLR8, TLR9, and TNFR-associated factor 6) were downregulated, whereas anti-inflammatory TLRs (single Ig IL-1-related receptor [SIGIRR] and ST2) were upregulated. ELISA showed that VIP modestly downregulated phosphorylated inhibitor of NF-κB kinase subunit α but upregulated ST2 ~2-fold. SIGIRR was also upregulated, whereas TLR4 immunostaining was reduced in cornea; all confirmed the mRNA data. To determine whether VIP effects were cAMP dependent, mice were injected with small interfering RNA for type 7 adenylate cyclase (AC7), with or without VIP treatment. After silencing AC7, changes in mRNA levels of TLR1, TNFR-associated factor 6, and ST2 were seen and unchanged with addition of VIP, indicating that their regulation was cAMP dependent. In contrast, changes were seen in mRNA levels of conserved helix-loop-helix ubiquitous kinase, IRAK1, 2, TLR4, 9 and SIGIRR following AC7 silencing alone; these were modified by VIP addition, indicating their cAMP independence. In vitro studies assessed the effects of VIP on TLR regulation in macrophages and Langerhans cells. VIP downregulated mRNA expression of proinflammatory TLRs while upregulating anti-inflammatory TLRs in both cell types. Collectively, the data provide evidence that VIP downregulates proinflammatory TLRs and upregulates anti-inflammatory TLRs and that this regulation is both cAMP dependent and independent and involves immune cell types found in the infected cornea.
Asunto(s)
Regulación hacia Abajo/inmunología , Mediadores de Inflamación/antagonistas & inhibidores , Queratitis/inmunología , Infecciones por Pseudomonas/inmunología , Receptores Toll-Like/antagonistas & inhibidores , Receptores Toll-Like/biosíntesis , Regulación hacia Arriba/inmunología , Péptido Intestinal Vasoactivo/fisiología , Animales , Células Cultivadas , Femenino , Mediadores de Inflamación/administración & dosificación , Mediadores de Inflamación/metabolismo , Queratitis/metabolismo , Queratitis/microbiología , Ratones , Ratones Endogámicos BALB C , Ratones Endogámicos C57BL , Infecciones por Pseudomonas/metabolismo , Infecciones por Pseudomonas/microbiología , Pseudomonas aeruginosa , Receptores Toll-Like/uso terapéutico , Péptido Intestinal Vasoactivo/administración & dosificaciónRESUMEN
New developments in the field of allergy and immunology have yielded a variety of novel therapeutic approaches in recent years, and more agents are at the clinical trial stage. Among the therapeutic approaches discussed in this review are Toll-like receptor agonists, immunostimulatory oligodeoxynucleotides, orally and parenterally administered cytokine blockers, and specific cytokine receptor antagonists. Transcription factor modulators targeting syk kinase, peroxisome proliferator-activated receptor-gamma, and nuclear factor-kappaB are also being evaluated in the treatment of asthma. The anti-IgE monoclonal antibody omalizumab has established effectiveness in patients with allergic asthma, but the criteria for selecting patients who are most likely to benefit from it are less clear. This review summarizes data from human clinical trials with immunomodulators to discuss the rationale for their use, their efficacy, and adverse events associated with them.
Asunto(s)
Asma/tratamiento farmacológico , Factores Inmunológicos/uso terapéutico , Ensayos Clínicos como Asunto , Citocinas/antagonistas & inhibidores , Citocinas/farmacología , Humanos , Oligodesoxirribonucleótidos/uso terapéutico , Receptores de Citocinas/antagonistas & inhibidores , Receptores de Citocinas/uso terapéutico , Receptores Toll-Like/agonistas , Receptores Toll-Like/uso terapéutico , Resultado del TratamientoRESUMEN
Desde sua descoberta, os receptores do tipo Toll (TLRs) têm sido envolvidos em quase todas as doenças que afetam a saúde humana. Seu papel na proteção contra vários patógenos, incluindo protozoários está bem estabelecido. Entretanto, pouco se sabe sobre o papel dos TLRs na malária. No presente estudo, investigamos o papel dos TLRs. durante a malária murina e humana. Nossos resultados mostraram que camundongos com deficiência para MyD88, um adaptador essencial para a sinalização dos TLRs, produzem níveis de citocinas pró-inflamatórias significativamente menores e apresentam sintomas mais amenos durante a infecção por Plasmodium chabaudi. Entretanto, estes animais retêm a capacidade de controlar a parasitemia sugerindo que os TLRs possuam um papel na patogênese e não na proteção contra a malária. Posteriormente, mostramos que ambas, a infecção natural humana por P. falciparum e a experimental murina por P. chabaudi, aumentam a expressão e a responsividade dos TLRs nas células do sistema imune inato. O estado hiper-responsivo das células durante a malária é derivado da ativação de TLR9 e a produção de IFN por células T, levando a uma alta susceptibilidade ao choque séptico durante a malária aguda. Finalmente, em colaboração com a EISAI Research Institute, desenvolvemos um antagonista de TLR9 e testamos seu efeito na Malária Cerebral (CM), uma das manifestações clínicas mais graves da malária. O tratamento oral com este composto inibiu os sintomas, tais como. extravasamento vascular cerebral, protegendo camundongos da morte por CM. Em conjunto, nossos resultados mostram um importante papel dos TLRs, especialmente TLR9, na patogênese da malária e que a intervenção na função destes receptores é uma potencial quimioterapia anti-inflamatória contra essa doença
Asunto(s)
Humanos , Animales , Cobayas , Ratones , Inmunidad Innata/inmunología , Malaria/inmunología , Plasmodium falciparum/parasitología , Receptores Toll-Like/uso terapéutico , Receptores de Citocinas/uso terapéuticoRESUMEN
Desde sua descoberta, os receptores do tipo Toll (TLRs) têm sido envolvidos em quase todas as doenças que afetam a saúde humana. Seu papel na proteção contra vários patógenos, incluindo protozoários está bem estabelecido. Entretanto, pouco se sabe sobre o papel dos TLRs na malária. No presente estudo, investigamos o papel dos TLRs. durante a malária murina e humana. Nossos resultados mostraram que camundongos com deficiência para MyD88, um adaptador essencial para a sinalização dos TLRs, produzem níveis de citocinas pró-inflamatórias significativamente menores e apresentam sintomas mais amenos durante a infecção por Plasmodium chabaudi. Entretanto, estes animais retêm a capacidade de controlar a parasitemia sugerindo que os TLRs possuam um papel na patogênese e não na proteção contra a malária. Posteriormente, mostramos que ambas, a infecção natural humana por P. falciparum e a experimental murina por P. chabaudi, aumentam a expressão e a responsividade dos TLRs nas células do sistema imune inato. O estado hiper-responsivo das células durante a malária é derivado da ativação de TLR9 e a produção de IFN por células T, levando a uma alta susceptibilidade ao choque séptico durante a malária aguda. Finalmente, em colaboração com a EISAI Research Institute, desenvolvemos um antagonista de TLR9 e testamos seu efeito na Malária Cerebral (CM), uma das manifestações clínicas mais graves da malária. O tratamento oral com este composto inibiu os sintomas, tais como. extravasamento vascular cerebral, protegendo camundongos da morte por CM. Em conjunto, nossos resultados mostram um importante papel dos TLRs, especialmente TLR9, na patogênese da malária e que a intervenção na função destes receptores é uma potencial quimioterapia anti-inflamatória contra essa doença
Asunto(s)
Humanos , Animales , Cobayas , Ratones , Inmunidad Innata/inmunología , Malaria/inmunología , Plasmodium falciparum/parasitología , Receptores de Citocinas/uso terapéutico , Receptores Toll-Like/uso terapéuticoRESUMEN
Intrauterine infections represent a significant threat to fetal well-being and pregnancy outcome. Recent studies suggest that non-immune cells of the maternal-fetal interface can actively recognize and respond to microbes through pattern recognition receptors, in order to control pathogens that may compromise the pregnancy. However, these same innate immune responses may inadvertently lead to excessive inflammation or apoptosis at the maternal-fetal interface. Thus, pattern recognition receptors may play a key role in infection-related pregnancy complications. This review discusses what is currently known about the role of Toll-like receptors and NOD-like receptors in controlling infections at the maternal-fetal interface, and what impact their function may have on pregnancy.
Asunto(s)
Proteína Adaptadora de Señalización NOD1/inmunología , Proteína Adaptadora de Señalización NOD2/inmunología , Placenta/inmunología , Complicaciones Infecciosas del Embarazo/inmunología , Receptores Toll-Like/inmunología , Animales , Infecciones por Chlamydia/etiología , Femenino , Humanos , Inmunidad Innata/genética , Inmunidad Innata/inmunología , Proteína Adaptadora de Señalización NOD1/metabolismo , Proteína Adaptadora de Señalización NOD1/uso terapéutico , Proteína Adaptadora de Señalización NOD2/metabolismo , Proteína Adaptadora de Señalización NOD2/uso terapéutico , Placenta/metabolismo , Placenta/microbiología , Embarazo , Complicaciones Infecciosas del Embarazo/diagnóstico , Complicaciones Infecciosas del Embarazo/genética , Complicaciones Infecciosas del Embarazo/microbiología , Complicaciones Infecciosas del Embarazo/prevención & control , Transducción de Señal/inmunología , Receptores Toll-Like/metabolismo , Receptores Toll-Like/uso terapéuticoRESUMEN
This study has shown that IFN-alpha/beta signaling is crucial for combating primary herpes simplex virus type 2 (HSV-2) infection and for responding to immunotherapy using ligands to TLR3, 7 and 9, but not for vaccine-induced immunity. Both genital viral replication and the disease progression were enhanced in HSV-2-infected mice lacking the IFN-alpha/beta receptor (IFN-alpha/betaR-/-). IFN-alpha/betaR-/- mice were, however, able to mount a normal HSV-2-specific Th1 response and acquired sterilizing immunity following vaccination. Anti-viral treatments using agonists to TLR3, 7 and 9 by administration of synthetic dsRNA, imiquimod and oligonucleotides containing unmethylated CpG motifs, respectively, were strongly dependent on IFN-alpha/beta receptor signaling for their efficacy. Even though all treatments had a weak impact on local vaginal viral replication in infected IFN-alpha/betaR-/- animals, they did not affect disease progression or mortality in these animals as opposed to wild type controls where all three treatments reduced viral replication as well as disease severity and mortality. Lack of IFN-alpha/betaR signaling also blocked production of IFN-gamma and TNF-alpha in response to TLR9 activation. These studies have shown that IFN-alpha/beta receptor signaling is important for multiple events in the anti-viral defense.
Asunto(s)
Herpes Genital/inmunología , Herpesvirus Humano 2 , Interferón-alfa/metabolismo , Interferón beta/metabolismo , Receptor de Interferón alfa y beta/metabolismo , Receptores Toll-Like/metabolismo , Animales , Antivirales/uso terapéutico , Femenino , Herpes Genital/tratamiento farmacológico , Herpes Genital/metabolismo , Herpes Genital/virología , Herpesvirus Humano 2/inmunología , Herpesvirus Humano 2/metabolismo , Interferón-alfa/inmunología , Interferón-alfa/uso terapéutico , Interferón beta/inmunología , Interferón beta/uso terapéutico , Interferón gamma/inmunología , Interferón gamma/metabolismo , Ratones , Poli I-C/farmacología , Transducción de Señal , Receptores Toll-Like/agonistas , Receptores Toll-Like/fisiología , Receptores Toll-Like/uso terapéutico , Factor de Necrosis Tumoral alfa/metabolismoRESUMEN
Toll like receptors (TLRs) are 'pattern recognition proteins' that discriminate between self and non-self. They interact with products of infectious agents to activate cells of the innate immune system and also stimulate the adaptive immune system. Intracellular and extracellular TLRs recognise a wide range of viruses leading to the production of different cytokines. In this paper, we summarise the types of TLRs that recognise viruses, the cytokines produced, the specific cell types involved and the activation pathways that have been characterised. We also provide an overview of the viruses demonstrated to interact with TLRs. A greater understanding of relationships between viruses or viral products and TLRs should improve understanding of pathogenesis and lead to the development of new anti-viral therapies.
Asunto(s)
Receptores Virales/fisiología , Receptores Toll-Like/fisiología , Virosis/inmunología , Virus/inmunología , Virus/patogenicidad , Animales , Citocinas/biosíntesis , Humanos , Especificidad de la Especie , Receptores Toll-Like/uso terapéutico , Virulencia , Virosis/terapia , Virosis/virologíaRESUMEN
We report a new immunological treatment for advanced cutaneous melanoma which combines laser stimulation with topical application of a toll-like receptor agonist. This treatment, in situ photoimmunotherapy (ISPI), provides an alternative to traditional therapies for melanoma patients with cutaneous metastases. A 6-week cycle of ISPI is carried out on cutaneous metastases located in a designated 20 x 20 cm treatment area: 2 weeks of pretreatment with twice-daily topical applications of imiquimod (5% cream under plastic occlusion), with a laser treatment session at week 2 and again at week 4. Topical imiquimod is continued for the entire 6-week cycle. Two patients with late-stage melanoma were treated with ISPI. Patient 1 had the primary tumour and local metastases on the left arm, as well as metastatic tumours in the lungs [American Joint Committee on Cancer (AJCC) stage IV]. Patient 2 had a head and neck melanoma with multiple local metastases (AJCC stage IIIC), which had failed repeated attempts at surgical resection and high-dose radiation therapy. Patient 1 is now free of all clinically detectable tumours (including the lung metastases) >20 months after the first treatment cycle. Patient 2 has been free of any clinical evidence of the tumour for over 6 months. These two cases demonstrate that ISPI can clear local tumour and trigger beneficial systemic responses, with a side-effect profile that compares favourably with other treatments for advanced melanoma.